Last reviewed · How we verify
Gemcitabine combined with nab-paclitaxel
Gemcitabine combined with nab-paclitaxel is a Chemotherapy combination (nucleoside analog + taxane) Small molecule drug developed by Pancreatic Cancer Action Network. It is currently in Phase 3 development for Metastatic pancreatic cancer, Locally advanced pancreatic cancer.
Gemcitabine and nab-paclitaxel work synergistically to disrupt cancer cell division by inhibiting DNA synthesis and microtubule dynamics, respectively.
Gemcitabine and nab-paclitaxel work synergistically to disrupt cancer cell division by inhibiting DNA synthesis and microtubule dynamics, respectively. Used for Metastatic pancreatic cancer, Locally advanced pancreatic cancer.
At a glance
| Generic name | Gemcitabine combined with nab-paclitaxel |
|---|---|
| Sponsor | Pancreatic Cancer Action Network |
| Drug class | Chemotherapy combination (nucleoside analog + taxane) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that interferes with DNA replication and repair in rapidly dividing cancer cells. Nab-paclitaxel (albumin-bound paclitaxel) stabilizes microtubules and prevents cell division. The combination leverages complementary mechanisms to enhance cytotoxic effects against pancreatic cancer cells while the albumin-binding of nab-paclitaxel improves drug delivery and reduces toxicity compared to conventional paclitaxel.
Approved indications
- Metastatic pancreatic cancer
- Locally advanced pancreatic cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Nausea and vomiting
- Fatigue
- Diarrhea
- Mucositis
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
- CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (PHASE1)
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (PHASE3)
- A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (PHASE2, PHASE3)
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine combined with nab-paclitaxel CI brief — competitive landscape report
- Gemcitabine combined with nab-paclitaxel updates RSS · CI watch RSS
- Pancreatic Cancer Action Network portfolio CI
Frequently asked questions about Gemcitabine combined with nab-paclitaxel
What is Gemcitabine combined with nab-paclitaxel?
How does Gemcitabine combined with nab-paclitaxel work?
What is Gemcitabine combined with nab-paclitaxel used for?
Who makes Gemcitabine combined with nab-paclitaxel?
What drug class is Gemcitabine combined with nab-paclitaxel in?
What development phase is Gemcitabine combined with nab-paclitaxel in?
What are the side effects of Gemcitabine combined with nab-paclitaxel?
Related
- Drug class: All Chemotherapy combination (nucleoside analog + taxane) drugs
- Manufacturer: Pancreatic Cancer Action Network — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic pancreatic cancer
- Indication: Drugs for Locally advanced pancreatic cancer
- Compare: Gemcitabine combined with nab-paclitaxel vs similar drugs
- Pricing: Gemcitabine combined with nab-paclitaxel cost, discount & access